A new study adds to evidence to suggest the main ingredient in Novo Nordisk’s injectable drug for type 2 diabetes may ...

A large study adds to evidence that the main ingredient in Novo Nordisk's injectable GLP-1 drug for type 2 diabetes may ...

GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

Recent studies highlight the risks of semaglutide, a main ingredient in diabetes treatments, in increasing eye condition ...

Semaglutide — the powerful ingredient behind Wegovy and Ozempic — has long been ... seems to be promising in reducing the risk of Alzheimer's disease and related dementias (ADRD)'.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

A new study adds to evidence to suggest the main ingredient in Novo Nordisk’s injectable drug for type 2 diabetes may increase patients’ risk for a dangerous eye condition ... the active ingredient in ...